Igencia, Inc. (Igenica)

Oncology Corporate Profile

HQ Location

863 Mitten Rd., Suite 102
Burlingame, CA 94010

Company Description

Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients.

Website: http://www.igenica.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
IGN523monoclonal antibodyAcute Myelogenous Leukemia (AML)I
IGN-786monoclonal antibodyAcute Myelogenous Leukemia (AML)Preclinical
IGN-786monoclonal antibodyChronic Lymphocytic Leukemia (CLL)Preclinical
IGN523monoclonal antibodyChronic Lymphocytic Leukemia (CLL)Preclinical
IGN523monoclonal antibodyMultiple MyelomaPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.igenica.com/

Recent News Headlines

There are no news items to display